Phosphohistone H3 and Ki-67 Labeling Indices in Cytologic Specimens from Well-Differentiated Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas: A Comparative Analysis Using Automated Image Cytometry

被引:17
|
作者
Fung, Adele D. [1 ]
Cohen, Cynthia [1 ]
Kavuri, Sravankumar [2 ]
Lawson, Diane [1 ]
Gao, Xin [1 ]
Reid, Michelle D. [1 ]
机构
[1] Emory Univ, Sch Med, Dept Pathol, Atlanta, GA 30322 USA
[2] Georgia Hlth Sci Univ, Dept Pathol, Augusta, GA USA
关键词
Phosphohistone H3; Ki-67 labeling index; Well-differentiated neuroendocrine tumors; Gastrointestinal tract; Pancreas; Automated cellular imaging system; CELL-CYCLE PHASE; ENDOCRINE TUMORS; IMMUNOHISTOCHEMICAL METHOD; PROLIFERATIVE INDEX; BREAST-CANCER; MITOTIC INDEX; NEOPLASMS; MELANOMA; METAANALYSIS; EXPRESSION;
D O I
10.1159/000351475
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Background: Ki-67 proliferation index was recently incorporated in the grading of neuroendocrine neoplasms (NENs) of the gastrointestinal tract (GIT) and pancreas. These are now divided into well-differentiated neuroendocrine tumors (WDNETs, grades 1 and 2) and poorly differentiated neuroendocrine carcinomas (grade 3). While Ki-67 is an established proliferation marker in NENs, phosphohistone H3 (PHH3), a newer marker of mitotic activity, is not. Methods: We determined Ki-67 and PHH3 indices on cytologic samples from WDNETs of the GIT and pancreas using an automated cellular imaging system (ACIS (R)). Results:There was a strong correlation between Ki-67 and PHH3 indices generated by ACIS on cytologic samples. However, in some cases the two stains caused conflicting grades within the same tumor. Conclusion: Both antibodies stain cells in different phases of the cell cycle which may cause discordant grades, thus affecting patient management and prognostication. Ki-67 staining is stronger than PHH3, making 'hot spots' easier to identify on ACIS. Ki-67 is more ideal than PHH3 for staining NENs, especially in tumors with borderline grades. Because PHH3 generates lower mitotic indices it should not be used as a proliferation marker in NENs until its expression has been further characterized. (C) 2013 S. Karger AG, Basel
引用
收藏
页码:501 / 508
页数:8
相关论文
共 17 条
  • [11] The Impact of Phosphohistone-H3-Assisted Mitotic Count and Ki67 Score in the Determination of Tumor Grade and Prediction of Distant Metastasis in Well-Differentiated Pancreatic Neuroendocrine Tumors
    Sari, Sule Ozturk
    Taskin, Orhun Cig
    Gundogdu, Gokcen
    Yegen, Gulcin
    Onder, Semen
    Keskin, Metin
    Saglam, Sezer
    Ozluk, Yasemin
    Gulluoglu, Mine
    Mete, Ozgur
    ENDOCRINE PATHOLOGY, 2016, 27 (02) : 162 - 170
  • [12] Reappraisal of the Utility of Mitosis, Ki67 Index, and SSTR2 Expression in the Differential Diagnosis between Grade 3 Well-differentiated Neuroendocrine Tumor and Poorly Differentiated Neuroendocrine Carcinoma of the Gastrointestinal Tract and Pancreas
    Sweeney, Jacob
    Yang, Zhaohai
    LABORATORY INVESTIGATION, 2021, 101 (SUPPL 1) : 478 - 479
  • [13] Reappraisal of the Utility of Mitosis, Ki67 Index, and SSTR2 Expression in the Differential Diagnosis between Grade 3 Well-differentiated Neuroendocrine Tumor and Poorly Differentiated Neuroendocrine Carcinoma of the Gastrointestinal Tract and Pancreas
    Sweeney, Jacob
    Yang, Zhaohai
    MODERN PATHOLOGY, 2021, 34 (SUPPL 2) : 478 - 479
  • [14] Diagnostic utility of p53 and Ki-67 labeling indices and flow cytometric DNA ploidy analysis in the distinction of well-differentiated peritoneal mesotheliomas from reactive mesothelial proliferations
    Kaleem, Z
    Caughron, S
    Loggie, B
    Gatalica, Z
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2004, 122 (04) : 642 - 642
  • [15] Subgroup analysis by Ki-67 and baseline CgA of the randomized, placebo-controlled phase 3 study of surufatinib in advanced well-differentiated pancreatic neuroendocrine tumors (SANET-p).
    Yu, Xianjun
    Xu, Jianming
    Shen, Lin
    Bai, Chunmei
    Li, Jie
    Zhou, Zhiwei
    Li, Zhiping
    Li, Enxiao
    Yuan, Xianglin
    Chi, Yihebali
    Yin, Yongmei
    Lou, Wenhui
    Xu, Nong
    Bai, Yuxian
    Zhang, Tao
    Xiu, Dianrong
    Wang, Xiuwen
    Guan, Sha
    Xu, Qian
    Su, Weiguo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [16] Subgroup Analysis by Ki-67 and Primary Tumor Origins of the Randomized, Placebo-Controlled Phase 3 Study of Surufatinib in Advanced Well-Differentiated Extrapancreatic Neuroendocrine Tumors (SANET-ep)
    Zhou, Zhiwei
    Xu, Jianming
    Shen, Lin
    Li, Jie
    Bai, Chunmei
    Chi, Yihebali
    Li, Zhiping
    Xu, Nong
    Li, Enxiao
    Liu, Tianshu
    Bai, Yuxian
    Yuan, Ying
    Li, Xingya
    Wang, Xiuwen
    Chen, Jia
    Wang, Wei
    Guan, Sha
    Fan, Songhua
    Su, Weiguo
    PANCREAS, 2022, 51 (03) : E43 - E43
  • [17] Open-Source Automated Digital Image Analysis and ChatGPT 4.0 Color Segmentation as Accurate Alternatives to Manual Counting for Ki67 Proliferation Index Assessment in Gastroenteropancreatic (GEP) Well-differentiated Neuroendocrine Tumors (WD-NETs)
    Padmanabha, Nandan
    Oganesyan, Ruben
    O'Brien, Laurie
    Li, Debbie
    Widener, Shaelyn
    Yilmaz, Osman
    Deshpande, Vikram
    Gonzalez, Raul
    Collins, Laura
    Vyas, Monika
    LABORATORY INVESTIGATION, 2024, 104 (03) : S1605 - S1607